Isabel Casimiro is an Endocrinology/Metabolic physician affiliated with University of Hawaiʻi at Mānoa. OpenAlex indexes 30 publications with 732 citations (h-index 13).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
550 S Beretania St Ste 202
Honolulu, HI 968132496
Telephone
808-691-8526Provider last certified this registry record 25 Jul 2022.
Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year20253 payments
- Esperion Therapeutics, Inc.Program year20252 payments
- Tandem Diabetes Care, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
57.2%GLP-1 receptor agonist19.1%Ozempic51%Trulicity21%Mounjaro19%Rybelsus10%Part D<11 patientsInsulin Analog13.8%Lantus Solostar28%Novolog Flexpen19%Basaglar Kwikpen U-10016%Tresiba Flextouch U-10010%Insulin Aspart Flexpen9%Humalog Kwikpen U-2007%Humalog Kwikpen U-1007%Toujeo Solostar5%Part D<11 patients+ 7 more classes in this area
Hormonal (systemic)
18.5%l-Thyroxine14.6%Levothyroxine Sodium86%Synthroid14%Part D≥62 patientsl-Triiodothyronine2.4%Liothyronine Sodium100%Part D≥14 patients+ 2 more classes in this area
Cardiovascular
15.5%Statin7%Atorvastatin Calcium100%Part D≥41 patientsAngiotensin receptor blocker (ARB)4%Losartan Potassium52%Irbesartan48%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- SAT-409 Evaluating the Role of Liothyronine and Levothyroxine Combination Therapy in Persistent Hypothyroidism Symptoms: A Case Series
Journal of the Endocrine Society
2025 - 12-Lipoxygenase inhibition improves glucose homeostasis and obesity-associated inflammation in human gene replacement mice
bioRxiv (Cold Spring Harbor Laboratory)
2025 - Combination therapy with levothyroxine and liothyronine in hypothyroid patients with persistent symptoms: A case series
Journal of Clinical and Translational Endocrinology Case Reports
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Cecilia Shikuma, MD
University of Hawaiʻi at Mānoa
Todd Seto, MD
University of Hawaiʻi at Mānoa
Brian Issell, MD, FACP
University of Hawaiʻi at Mānoa
Naoky Tsai, MD
University of Hawaiʻi at Mānoa
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”